What radiolabeled FAPI pet can add in breast cancer? A systematic review from literature

to provide an overview of the current available data about FAPI PET in breast cancer patients, with a perspective point of view. a literature search for studies about FAPI PET in the last 5 years (from 2017 to january 2023) was carried out on MEDLINE databases, such as pubmed, EMBASE, web of science and google scholar using the following keywords: "PET" AND "FAPI" AND "breast cancer" AND "fibroblast imaging". the critical appraisal skills program (CASP) checklist for diagnostic test studies was used for testing the quality of selected papers. 13 articles were selected, including 172 patients affected by breast cancer who underwent FAPI-based PET images. CASP checklist was used in 5/13 papers, demonstrating a general low quality. different types of FAPI-based tracers were used. no difference in terms of FAPI uptake was reported based on the histopathological characteristics, such as immunohistochemistry and grading of breast cancer. FAPI demonstrated more lesions and yielded much higher tumor-to-background ratios than 2-[18F]FDG. preliminary experiences with FAPI PET in breast cancer showed some advantages than the current available 2-[18F]FDG, although prospective trials are needed to further evaluate its diagnostic utility in clinical practice.